"Lingering respiratory symptoms are not exclusive to COVID-19; influenza and RSV infections can also result in prolonged health complications, including pulmonary dysfunction and cardiovascular events, particularly in hospitalized individuals."
As the world grapples with the enduring impact of Long COVID, emerging research underscores that other common respiratory viruses, such as influenza and respiratory syncytial virus (RSV), can also inflict a lasting toll on health. A comprehensive systematic review, published in the journal Respirology, consolidates findings from numerous observational studies, revealing that post-viral syndromes are a significant, yet often underexplored, consequence of these infections. The implications of this research are particularly pertinent as the United States enters its annual respiratory virus season, prompting a reevaluation of the long-term costs associated with infection beyond the acute illness.
The systematic review, spearheaded by a team from Duke-NUS Medical School in Singapore, meticulously analyzed 13 observational studies encompassing over 631,000 individuals. The research spanned from January 2004 to August 2025, providing a substantial historical dataset to assess the protracted effects of non-COVID respiratory infections. The authors emphasize the critical importance of understanding these post-infection sequelae to inform clinical care strategies and public health policies, given the vast number of people affected by these viruses annually.
A Spectrum of Post-Infection Complications
Influenza emerged as the most frequently studied infection within the review, with lung dysfunction consistently identified as a primary lingering problem. Early research, such as a 2009 study involving 48 participants, indicated that a significant majority (54%) exhibited abnormal pulmonary function 11 to 13 months after an acute influenza infection. Approximately one-third of these individuals continued to report respiratory symptoms a year post-infection, and over 40% experienced a reduction in exercise tolerance.
Further investigation into severe influenza cases, like a 2017 study of 47 survivors, revealed persistent issues with oxygen transfer from the lungs to the bloodstream, with 78% demonstrating impaired efficiency up to two years after the initial illness. While these smaller sample sizes warrant cautious interpretation, the findings from larger datasets within the review corroborate these trends. The review’s strength lies in its synthesis of existing data, though it acknowledges that some of the larger studies relied on insurance and hospital records rather than direct clinical examinations, a limitation inherent in retrospective observational research.
The persistence of respiratory symptoms long after the acute phase of influenza has been well-documented. Among 951 Australians diagnosed with influenza, a notable 23% still reported symptoms after 12 weeks, with 4.4% experiencing moderate to severe difficulties in performing daily activities. In the United States, a study of 20,844 hospitalized patients found that one in ten continued to suffer from a cough or shortness of breath six months post-infection. This particular finding pertains to a more severe cohort, as hospitalization generally indicates a more serious initial illness.
Intriguingly, the review also highlighted cognitive and sensory impairments following influenza, mirroring some of the hallmark symptoms of Long COVID. An analysis of German insurance records, covering nearly 570,000 individuals, reported that 23% experienced memory problems and 44% had a distorted sense of taste or a reduced sense of smell three to six months after their acute illness. These observations lend credence to the review authors’ argument that the post-viral aftermath of non-COVID respiratory infections has been historically underdescribed, largely due to the public’s increasing familiarity with the concept through the lens of COVID-19.
Cardiovascular Concerns Following RSV
The review’s examination of Respiratory Syncytial Virus (RSV) focused on its impact on the cardiovascular system, a finding that sets it apart from the predominantly pulmonary issues observed with influenza. Of the two studies that investigated RSV, both pointed towards an increased risk of heart-related events in the months following infection.
In a U.S. study involving 441 hospitalized adults with RSV, 16% experienced a cardiac event between 29 days and six months after their acute infection. Crucially, the monthly incidence of cardiovascular events during this post-infection period was 1.6 times higher compared to the six months preceding hospitalization. This suggests a potential inflammatory or physiological response triggered by the RSV infection that extends to the heart.
A separate cohort study conducted in Singapore with 1,553 adults who had RSV found that 2.1% developed new-onset cardiac disorders. While these percentages differ, the researchers attribute these variations to differences in study populations and diagnostic criteria rather than a contradiction in findings. The convergence of evidence, however, suggests a tangible link between RSV infection and subsequent cardiovascular complications.
The review also touched upon human metapneumovirus, a less commonly discussed respiratory virus. In a small study of 92 hospitalized adults, a significant 55% reported at least one persistent symptom three to nine months later. The most prevalent among these were shortness of breath, followed by fatigue and cough, indicating a broader pattern of prolonged illness following common respiratory infections.
Navigating the Limitations and Looking Ahead
It is imperative to acknowledge the limitations of the reviewed studies. The authors explicitly state that the majority of the included research was observational and primarily focused on hospitalized patients. This means that the reported percentages likely represent a more severe end of the spectrum and may not accurately reflect the prevalence of lingering symptoms in individuals who experienced mild infections managed at home. The review cannot definitively establish causality; it demonstrates an association between infection and subsequent symptoms, but does not prove that the virus directly caused the long-term issues.
Furthermore, the varied outcome measures and follow-up periods across the studies contribute to the wide range of reported figures. The authors advocate for the adoption of standardized definitions and outcome measures in future research to enable a more accurate quantification of the post-viral burden.
The findings do not alter current medical guidance on managing influenza and RSV. However, they strongly reinforce the importance of preventive measures, particularly vaccination. Older adults, individuals with pre-existing heart or lung conditions, and those with compromised immune systems are identified as groups at higher risk for severe outcomes and subsequent long-term complications. Vaccination against influenza and RSV remains the most robust intervention for preventing severe infections, and studies, such as one on nursing home residents, have demonstrated the RSV vaccine’s effectiveness in preventing hospitalization and death. Major U.S. medical organizations continue to issue seasonal vaccine recommendations for flu, COVID-19, and RSV, underscoring their continued importance.
For individuals experiencing persistent symptoms such as cough, breathlessness, chest discomfort, or a significant reduction in exercise capacity for two to three months following a respiratory infection, seeking clinical evaluation is a reasonable step. These symptoms may warrant further investigation, including pulmonary function testing. In cases of sudden chest pain, fainting, or severe breathlessness, immediate medical attention is crucial.
The implications of this review are clear: recovery from common respiratory infections is not always confined to the acute illness phase. Patients are encouraged to communicate any persistent symptoms to their healthcare providers, recognizing that these may not simply fade away and could indicate a longer recovery trajectory. By raising awareness of the post-viral sequelae of influenza and RSV, this research contributes to a more comprehensive understanding of the enduring impact of respiratory pathogens and underscores the need for continued vigilance and proactive health management.
